AstraZeneca PLC
2012 Annual General Meeting

26 April 2012

Welcome to our Annual General Meeting
AstraZeneca PLC
2012 Annual General Meeting

Louis Schweitzer
Chairman
AstraZeneca PLC
2012 Annual General Meeting

Shriti Vadera
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

Rudy Markham
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

Michele Hooper
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

Simon Lowth
Chief Financial Officer
AstraZeneca PLC
2012 Annual General Meeting

David Brennan
Chief Executive Officer
AstraZeneca PLC
2012 Annual General Meeting

Bruce Burlington
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

Jean-Philippe Courtois
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

Nancy Rothwell
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

Marcus Wallenberg
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting

John Varley
Non-Executive Director
AstraZeneca PLC
2012 Annual General Meeting
Geneviève Berger
AstraZeneca PLC
2012 Annual General Meeting

Graham Chipchase
AstraZeneca PLC
2012 Annual General Meeting

Leif Johansson
AstraZeneca PLC
2012 Annual General Meeting
AstraZeneca PLC
2012 Annual General Meeting

David Brennan
Chief Executive Officer
Our values

AstraZeneca is

- Focused
- Innovation-driven
- Integrated
- Global
- Biopharma

Our vision
Industry outlook

Growth Sector
- Increasing and ageing populations
- Expanding populations in new markets
- Significant unmet medical need
- Continued scientific and technological advance

Pressures on returns
- Decline in R&D productivity
- Established market price pressure
- Patent expiries and genericisation
Corporate strategic priorities

Making the most meaningful difference to patient health through great medicines

### Pipeline
- Transform R&D organisation
- Improve quantity and quality of output
- More outward-looking and collaborative
- Drive productivity

### Deliver the business
- Growth of current products
- Innovative channels to meet customer needs
- Drive growth in emerging markets
- Build stronger relationships with payers

### Business shape
- Reshape and simplify business
- Restructure to improve competitiveness
- Invest to drive growth
- Manage change in the right way

### People
- Acquiring and retaining talent
- Developing leaders
- Improving diversity
- Improving engagement

Manage for long-term shareholder value

Our values
## Corporate strategic priorities

**Pipeline**

- Transform R&D organisation
- Improve quantity and quality of output
- More outward-looking and collaborative
- Drive productivity
## Corporate strategic priorities

**Deliver the business**

- Growth of current products
- Innovative channels to meet customer needs
- Drive growth in emerging markets
- Build stronger relationships with payers
## Corporate strategic priorities

### Business shape

- Reshape and simplify business
- Restructure to improve competitiveness
- Invest to drive growth
- Manage change in the right way
# Corporate strategic priorities

## People

- Acquiring and retaining talent
- Developing leaders
- Improving diversity
- Improving engagement
Corporate strategic priorities

Values

• Committed to acting responsibly and to the sustainable development of our business
• Integrity and high ethical standards
• Global Policy on External Interactions
• Revised IFPMA Code of Conduct
AstraZeneca PLC
2012 Annual General Meeting
## Headline results: 1Q 2012

<table>
<thead>
<tr>
<th></th>
<th>2012 $m</th>
<th>2011 $m</th>
<th>Actual growth</th>
<th>CER growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>7,349</td>
<td>8,292</td>
<td>-11%</td>
<td>-11%</td>
</tr>
<tr>
<td>Core Operating Profit</td>
<td>2,997</td>
<td>3,678</td>
<td>-19%</td>
<td>-18%</td>
</tr>
<tr>
<td>Reported EPS</td>
<td>$1.28</td>
<td>$2.08</td>
<td>-38%</td>
<td>-39%</td>
</tr>
<tr>
<td>Core EPS</td>
<td>$1.81</td>
<td>$2.23</td>
<td>-19%</td>
<td>-19%</td>
</tr>
</tbody>
</table>
## Key brand revenue summary: 1Q 2012

<table>
<thead>
<tr>
<th></th>
<th>2012 $m</th>
<th>2011 $m</th>
<th>CER growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crestor</td>
<td>1,500</td>
<td>1,478</td>
<td>+2%</td>
</tr>
<tr>
<td>Seroquel IR</td>
<td>754</td>
<td>1,006</td>
<td>-25%</td>
</tr>
<tr>
<td>Seroquel XR</td>
<td>384</td>
<td>339</td>
<td>+14%</td>
</tr>
<tr>
<td>Symbicort</td>
<td>723</td>
<td>752</td>
<td>-3%</td>
</tr>
<tr>
<td>Arimidex</td>
<td>144</td>
<td>233</td>
<td>-39%</td>
</tr>
<tr>
<td>Nexium</td>
<td>953</td>
<td>1,161</td>
<td>-18%</td>
</tr>
</tbody>
</table>
### Regional revenue performance: 1Q 2012

<table>
<thead>
<tr>
<th>Region</th>
<th>2012 $m</th>
<th>2011 $m</th>
<th>CER growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenue</td>
<td>7,349</td>
<td>8,292</td>
<td>-11%</td>
</tr>
<tr>
<td>US</td>
<td>2,920</td>
<td>3,304</td>
<td>-12%</td>
</tr>
<tr>
<td>Western Europe</td>
<td>1,775</td>
<td>2,235</td>
<td>-19%</td>
</tr>
<tr>
<td>Established Rest of World</td>
<td>1,238</td>
<td>1,321</td>
<td>-9%</td>
</tr>
<tr>
<td>Emerging Rest of World</td>
<td>1,416</td>
<td>1,432</td>
<td>+1%</td>
</tr>
</tbody>
</table>
## Headline results: 1Q 2012

<table>
<thead>
<tr>
<th></th>
<th>2012 $m</th>
<th>2011 $m</th>
<th>Actual growth</th>
<th>CER growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>7,349</td>
<td>8,292</td>
<td>-11%</td>
<td>-11%</td>
</tr>
<tr>
<td>Core Operating Profit</td>
<td>2,997</td>
<td>3,678</td>
<td>-19%</td>
<td>-18%</td>
</tr>
<tr>
<td>Reported EPS</td>
<td>$1.28</td>
<td>$2.08</td>
<td>-38%</td>
<td>-39%</td>
</tr>
<tr>
<td>Core EPS</td>
<td>$1.81</td>
<td>$2.23</td>
<td>-19%</td>
<td>-19%</td>
</tr>
</tbody>
</table>
AstraZeneca PLC
2012 Annual General Meeting
Resolutions

1. To receive the Company’s Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2011
2. To confirm dividends
3. To re-appoint KPMG Audit Plc, London as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect the following as Directors:
   a) Louis Schweitzer
   b) David Brennan
   c) Simon Lowth
   d) Geneviève Berger
   e) Bruce Burlington
   f) Graham Chipchase
   g) Jean-Philippe Courtois
   h) Leif Johansson
   i) Rudy Markham
   j) Nancy Rothwell
   k) Shriti Vadera
   l) John Varley
   m) Marcus Wallenberg
6. To approve the Directors’ Remuneration Report for the year ended 31 December 2011
7. To authorise limited EU political donations
8. To authorise the Directors to allot shares
9. To approve the New SAYE Scheme
10. To authorise the Directors to disapply pre-emption rights
11. To authorise the Company to purchase its own shares
12. To reduce the notice period for general meetings
AstraZeneca PLC
2012 Annual General Meeting
Resolutions

1. To receive the Company’s Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2011
2. To confirm dividends
3. To re-appoint KPMG Audit Plc, London as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect the following as Directors:
   a) Louis Schweitzer
   b) David Brennan
   c) Simon Lowth
   d) Geneviève Berger
   e) Bruce Burlington
   f) Graham Chipchase
   g) Jean-Philippe Courtois
   h) Leif Johansson
   i) Rudy Markham
   j) Nancy Rothwell
   k) Shriti Vadera
   l) John Varley
   m) Marcus Wallenberg
6. To approve the Directors’ Remuneration Report for the year ended 31 December 2011
7. To authorise limited EU political donations
8. To authorise the Directors to allot shares
9. To approve the New SAYE Scheme
10. To authorise the Directors to disapply pre-emption rights
11. To authorise the Company to purchase its own shares
12. To reduce the notice period for general meetings
AstraZeneca PLC
2012 Annual General Meeting

• Please place your completed Polling Card in one of the boxes as you leave the meeting room
• We expect to announce the results of the poll later today
• The results of the poll will also be published in the Investors section of our website, astrazeneca.com
AstraZeneca PLC
2012 Annual General Meeting

Thank you for attending and have a safe journey home